VISUALIZATION OF MONOAMINE OXIDASE IN HUMAN BRAIN

Chemistry and Medical Departments, Brookhaven National Laboratory, Upton NY 11973

Monoamine oxidase (MAO; EC: 1.4.3.4) is a flavin containing enzyme which exists in two subtypes, MAO A and MAO B. MAO A and B are different gene products and they also differ in their substrate and inhibitor selectivities and their cellular localizations. In human brain MAO B predominates (B:A = 4:1) and is largely compartmentalized in cell bodies of serotonergic neurons and in glia. Many studies of human brain MAO B post mortem report that MAO B increases with age and in neurodegenerative disease [1]. This is consistent with investigations showing that the number of glial cells increases with age in the normal human brain [2] and in neurodegenerative disease.

As an initial step in the investigation of the feasibility of detecting and tracking neurodegenerative processes in the living human brain, we measured brain MAO B in normal healthy subjects (n=21; age range 23-86; 9 females and 12 males; non-smokers). The studies followed the guidelines of the Human Subjects Research Committee at Brookhaven National Laboratory and subjects gave informed consent after the procedures had been explained to them. We used PET and deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) [3]. MAO B was assessed using a model term \( k_3 \) which is a function of MAO B activity. A blood to brain influx constant \( (K_1) \) which is related to brain blood flow was also calculated. Regions of interest were occipital cortex, frontal cortex, cingulate gyrus, parietal cortex, temporal cortex, pons, thalamus, basal ganglia, cerebellum and global regions.

The regional distribution of MAO B was highest in the basal ganglia and the thalamus with intermediate levels in the frontal cortex and cingulate gyrus and lowest levels in the parietal and temporal cortices and cerebellum. The model term \( k_3 \) showed a significant increase with age \((p<0.004)\) in all brain regions examined except for the cingulate gyrus (with a trend for the parietal cortex). The results of correlation analysis for the global region is shown in Figure 1A. The same patterns remained when the correlation analysis was performed separately for males and females.

[11C]L-Deprenyl-D2 has tracer characteristics which allow a plasma to brain transfer constant, a model term which is related to blood flow, to be extracted from dynamic PET data. In contrast to \( k_3 \) which increased with age, \( K_1 \) significantly \((p<0.01)\) decreased in all brain regions except for the pons and the cerebellum. The highest correlation coefficients were in the cingulate gyrus, the frontal cortex, the temporal cortex and the parietal cortex consistent with other studies. Individual data for \( K_1 \) for the global region vs age is shown in Figure 1B.
DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.
DISCLAIMER

Portions of this document may be illegible in electronic image products. Images are produced from the best available original document.
Figure 1. (A) Individual values of MAO B activity (represented by $\lambda k_3$) versus age; (B) Individual values of plasma to brain transfer constant ($K_1$) which is related to blood flow versus age.
This study confirms several post-mortem studies reporting increases in brain MAO B with age though the rate of increase is lower than most studies. The whole brain and the cortical regions and the basal ganglia, thalamus, pons and cerebellum showed an average increase of 7.1±1.3 %/decade. The frontal cortex showed a rate of increase of 5.7%/decade which is similar to that reported by Fowler and coworkers [4] but far lower than the increase of 51%/decade reported in a recent post-mortem study [5]. The only brain region where we observe no increase with age is the cingulate gyrus. Though the increases with age is statistically significant, it is noteworthy that there is also a large variability among subjects in the same age range as can be seen from Figure 1A. The factors which account for the difference in magnitude between this PET study and post-mortem studies (and to differences between post-mortem studies) and to the large intersubject variability are not known. However, it is likely that differences in subjects contributes to differences between different studies. In this regard, the difficulty in distinguishing mild dementia from normality in post mortem studies of normal aging have been noted and may have been a factor [2]. Smoking status was not controlled in the post-mortem studies and may have accounted for some of the differences based on the report that smokers have reduced brain MAO B [6]. It would be interesting and important to examine this issue retrospectively.

In summary, we have observed that brain MAO B increases with age in healthy normal subjects who show typical patterns of age related decreases in blood flow. However, the increases we observe are generally smaller than those reported for most post-mortem studies and there is also a relatively large variability in MAO B even within relatively small age ranges in this group of normal, healthy subjects. Thus the extent to which increases in brain MAO B reflects age-related increases in glial cells or whether there are other variables contributing to the results of this PET study and to the range of results reported in the literature requires further investigation.

This research was carried out at Brookhaven National Laboratory under contract DE-AC02-76CH00016 with the US Department of energy and supported by its Office of Health and environmental Research and also by the National Institutes of Health (NS 15638 and NS 15380). The authors are grateful to David Schlyer, Robert Carciello, Richard Ferrieri, Donald Warner, David Alexoff, Payton King, Noelwah Netusil, Thomas Martin, Darrin Jenkins, Christopher Wong, Carol Redvanly and Alfred Wolf for their advice and their assistance in performing these studies. They are also grateful to the subjects who volunteered for these studies.